{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T19:50:28Z","timestamp":1762026628448,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1053\/j.seminhematol.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:17:15Z","timestamp":1605266235000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis"],"prefix":"10.1053","volume":"57","author":[{"given":"Kristen M.","family":"O'Dwyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"28","key":"10.1053\/j.seminhematol.2020.11.004_bib0001","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.11.004_bib0002","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.11.004_bib0003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","article-title":"T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol","volume":"34","author":"Quist-Paulsen","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0004","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0005","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.11.004_bib0006","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1053\/j.seminhematol.2020.11.004_bib0007","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.11.004_bib0008","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia."},{"issue":"20","key":"10.1053\/j.seminhematol.2020.11.004_bib0009","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.11.004_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7188","key":"10.1053\/j.seminhematol.2020.11.004_bib0011","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature06840","article-title":"The earliest thymic progenitors for T cells possess myeloid lineage potential","volume":"452","author":"Bell","year":"2008","journal-title":"Nature"},{"issue":"7188","key":"10.1053\/j.seminhematol.2020.11.004_bib0012","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature06839","article-title":"Adult T-cell progenitors retain myeloid potential","volume":"452","author":"Wada","year":"2008","journal-title":"Nature"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.11.004_bib0014","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.11.004_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2013-03-491092","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.11.004_bib0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOH.0b013e3283623c61","article-title":"Early T-cell precursor acute lymphoblastic leukaemia","volume":"20","author":"Haydu","year":"2013","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.11.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.11.004_bib0018","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2020.11.004_bib0019","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.11.004_bib0020","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.11.004_bib0021","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1200\/JCO.1997.15.6.2222","volume":"15","author":"Nachman","year":"1997","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2020.11.004_bib0022","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children's Oncology Group Study[corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.11.004_bib0023","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.11.004_bib0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.11.004_bib0025","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.11.004_bib0026","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Gokbuget","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2020.11.004_bib0027","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1053\/j.seminhematol.2020.11.004_bib0028","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.11.004_bib0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.11.004_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2020.11.004_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/asheducation-2005.1.131","article-title":"Acute lymphoblastic leukemia: older patients and newer drugs","author":"Larson","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.11.004_bib0032","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"22","key":"10.1053\/j.seminhematol.2020.11.004_bib0033","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0034","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.11.004_bib0035","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"7380","key":"10.1053\/j.seminhematol.2020.11.004_bib0036","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a035246","article-title":"The genetics and mechanisms of T-cell acute lymphoblastic leukemia","volume":"10","author":"Gianni","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.11.004_bib0038","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.11.004_bib0039","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.11.004_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.11.004_bib0041","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.11.004_bib0042","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.11.004_bib0043","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2020.11.004_bib0044","unstructured":"Jabbour E., Pullarkat V., Lacayo N. Venetoclax and navitoclax in relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. EHA Library 06\/12\/20. 2020;294936."},{"issue":"9","key":"10.1053\/j.seminhematol.2020.11.004_bib0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.11.004_bib0046","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.11.004_bib0047","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.11.004_bib0048","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2020.11.004_bib0049","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2020.11.004_bib0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-Cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.11.004_bib0051","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0052","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.11.004_bib0053","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2020.11.004_bib0054","series-title":"2020 AACR Virtual Annual Meeting","article-title":"Clinical Safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia","author":"Wang","year":"2020"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.11.004_bib0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.leu.2402006","article-title":"Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate\/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study","volume":"15","author":"Petersdorf","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.11.004_bib0056","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.11.004_bib0057","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol."},{"issue":"5","key":"10.1053\/j.seminhematol.2020.11.004_bib0058","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.11.004_bib0059","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.V112.11.304.304","article-title":"First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation","volume":"112","author":"Goekbuget","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:03Z","timestamp":1758522483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196320300470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0037196320300470"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.11.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}